Dee Haslam is living proof that a CLL diagnosis doesn't have to define your life. Now she and her husband, Jimmy, want to ...

Cleveland Browns owners recently made a large donation for cancer research. Dee Haslam lives daily with a rare blood cancer ...

For BTK inhibitor selection in frontline CLL treatment, age, risk profile, and long-term sequencing strategy influence ...

A post hoc analysis evaluates zanubrutinib vs acalabrutinib-venetoclax in treatment naive chronic lymphocytic leukemia using indirect comparisons of data from two phase 3 trials.

Karen Fancher, PharmD, BCOP, associate professor of pharmacy practice at Duquesne University and clinical oncology specialist ...

Browns owners Dee and Jimmy Haslam have donated $12.5 million toward blood cancer research after Dee was diagnosed with ...

Dee and Jimmy Haslam, the managing partners of Haslam Sports Group and owners of the Cleveland Browns, are putting serious ...

The BRUIN CLL-322 trial evaluated the safety and efficacy of pirtobrutinib plus venetoclax and rituximab in previously treated CLL/SLL patients.

Six-year data show continuous zanubrutinib keeps CLL controlled longer than bendamustine-rituximab, including high-risk ...